Rising US measles cases spur drug development efforts

The United States is experiencing its highest number of measles cases in decades amid declining vaccination rates. Researchers have begun developing treatments for the virus and for vulnerable individuals.

Up until recently, the effectiveness of measles vaccination meant there was little medical or financial incentive to create treatments for the disease.

As cases climb, scientists are now working on drugs to assist those who become infected or face higher risks from the virus.

The shift reflects changing public health conditions in the country.

관련 기사

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
AI에 의해 생성된 이미지

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Researchers at Georgia State University have developed an oral drug that stopped a measles-like virus from transmitting between ferrets via air or contact. The treatment worked when given before or after exposure and shortened illness duration.

AI에 의해 보고됨

The São Paulo State Health Department confirmed two new measles cases in the state capital on Tuesday (30), bringing the total infections recorded in the state in 2026 to seven.

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

AI에 의해 보고됨

The Ministry of Health issued an epidemiological alert due to the unusual rise in Influenza B cases during the current period, according to the weekly Winter Campaign 2026 report.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부